ArticleNPJ breast cancer2025

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer.

Vivek Anand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.